Next Article in Journal
The Circulating Transcriptome as a Source of Biomarkers for Melanoma
Next Article in Special Issue
Novel Immunoregulatory Functions of IL-18, an Accomplice of TGF-β1
Previous Article in Journal
Targeted Delivery to Tumors: Multidirectional Strategies to Improve Treatment Efficiency
Previous Article in Special Issue
Exploiting NK Cell Surveillance Pathways for Cancer Therapy
Open AccessArticle

Functional Assessment for Clinical Use of Serum-Free Adapted NK-92 Cells

1
Center for Hematology and Regenerative Medicine, Department of Medicine Huddinge, Karolinska Institutet, 141 83 Stockholm, Sweden
2
NSU Cell Therapy Institute, Nova Southeastern University, Fort Lauderdale, FL 33314, USA
3
Haematology Centre, Karolinska University Hospital, 141 57 Huddinge, Sweden
4
Nanotechnology Research and Application Center, Sabanci University, 34956 Istanbul, Turkey
*
Author to whom correspondence should be addressed.
Authors contributed equally.
Cancers 2019, 11(1), 69; https://doi.org/10.3390/cancers11010069
Received: 15 November 2018 / Revised: 28 December 2018 / Accepted: 3 January 2019 / Published: 10 January 2019
(This article belongs to the Special Issue Natural Killer Cells and Cancer Therapy)
Natural killer (NK) cells stand out as promising candidates for cellular immunotherapy due to their capacity to kill malignant cells. However, the therapeutic use of NK cells is often dependent on cell expansion and activation with considerable amounts of serum and exogenous cytokines. We aimed to develop an expansion protocol for NK-92 cells in an effort to generate a cost-efficient, xeno-free, clinical grade manufactured master cell line for therapeutic applications. By making functional assays with NK-92 cells cultured under serum-free conditions (NK-92SF) and comparing to serum-supplemented NK-92 cells (NK-92S) we did not observe significant alterations in the viability, proliferation, receptor expression levels, or in perforin and granzyme levels. Interestingly, even though NK-92SF cells displayed decreased degranulation and cytotoxicity against tumor cells in vitro, the degranulation capacity was recovered after overnight incubation with 20% serum in the medium. Moreover, lentiviral vector-based genetic modification efficiency of NK-92SF cells was comparable with NK-92S cells. The application of similar strategies can be useful in reducing the costs of manufacturing cells for clinical use and can help us understand and implement strategies towards chemically defined expansion and genetic modification protocols. View Full-Text
Keywords: NK-92; NK cell; serum-free; immunotherapy NK-92; NK cell; serum-free; immunotherapy
Show Figures

Figure 1

MDPI and ACS Style

Chrobok, M.; Dahlberg, C.I.M.; Sayitoglu, E.C.; Beljanski, V.; Nahi, H.; Gilljam, M.; Stellan, B.; Sutlu, T.; Duru, A.D.; Alici, E. Functional Assessment for Clinical Use of Serum-Free Adapted NK-92 Cells. Cancers 2019, 11, 69.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop